Please assess the completion status of the following clinical trial:

Trial Title: Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer~* No prior chemotherapy~* Age: 20 and more~* Performance status: ECOG 0-3~* 1) Absolute neutrophil count at least 1,500/mm3 2) Platelet count at least 100,000/mm3 3) Bilirubin less than 1.5mg/dL 4) SGOT less than 100 IU/l 5) Serum creatinine less than 1.5mg/dL~* Written informed consent~Exclusion Criteria:~* Patients with ovarian borderline tumor~* Patients who have any evidence of the other cancer present within the last 5 years with the exception of carcinoma in situ or intramucosal cancer that is curable with local therapy~* Patients with active infection or uncontrolled diabetes~* Patients with unstable angina, or those who have had a myocardial infarction within the past 6 months, or patients with serious arrythmia that requires medication~* Patients who have a history of hypersensitivity to polyoxyethylated castor oil (Cremophor EL)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Drug: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
- 2 (Type: EXPERIMENTAL): Drug: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).